Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NESPA early immunotherapy in anti-Hu paraneoplastic sensory neuropathy
2023-506942-22-01Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of Human normal immunoglobulin G, cyclophosphamide and methylprednisolone in paraneoplastic sensory neuronopathy (PSN), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Clinical improvement on ONLS at 3 months. Planned start Mar 2024; status: authorised.
02
Drugs
Human normal immunoglobulin Gcyclophosphamidemethylprednisolone
03
Conditions
paraneoplastic sensory neuronopathy (PSN)
Beyond the preview
Go deeper on 2023-506942-22-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506942-22-01.